NCT06213129

Brief Summary

The aim of this study is to evaluate the effects of sodium and UF profiling on hemodynamic stability, interdialytic weight gain, and intradialytic complications

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2024

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

January 15, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 28, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2024

Completed
Last Updated

January 19, 2024

Status Verified

January 1, 2024

Enrollment Period

6 months

First QC Date

September 18, 2023

Last Update Submit

January 17, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • systolic and diastolic blood pressure

    The primary outcome is systolic blood pressure (80 \_130)mmhg and diastolic blood pressure within range (60\_80)mmhg, A blood pressure within this range is considered indicative of a better health outcome for the purposes of our research

    2 weeks

  • Dialysis symptoms index

    The Dialysis Symptom Index is a validated instrument to assess CKD-related unpleasant symptoms, and it is comprised of 30 questions about the presence of specifc symptoms For each question querying presence vs. absence of a specifc symptom, symptom severity is assessed using a five-point Likert scale, with each response ranging from 0 to 4 (i.e., a response of "0" indicates "no," whereas a response of "4" indicates "yes: very much"). The minimum-maxi- mum Dialysis Symptom Index score ranges from 0 to 120,with higher scores indicating worse outcome

    2 weeks

Interventions

Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

End-stage renal disease on regular HD

You may qualify if:

  • End-stage renal disease patients.
  • Patients on regular hemodialysis

You may not qualify if:

  • Patients who refuse to contribute in this study.
  • Hemodynamically unstable patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Coli L, La Manna G, Dalmastri V, De Pascalis A, Pace G, Santese G, Stefanio C, Ursino M, Zaca F, Stefoni S. Evidence of profiled hemodialysis efficacy in the treatment of intradialytic hypotension. Int J Artif Organs. 1998 Jul;21(7):398-402.

    PMID: 9745994BACKGROUND

Study Officials

  • youssef Saleh

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Neveen Hassan

CONTACT

Ragda Hassan, 3

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MA Researcher

Study Record Dates

First Submitted

September 18, 2023

First Posted

January 19, 2024

Study Start

January 15, 2024

Primary Completion

June 28, 2024

Study Completion

August 28, 2024

Last Updated

January 19, 2024

Record last verified: 2024-01